The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

The NHS should move away from a one-size-fits-all approach of starting everyone on the same medication, to more personalised ...

America’s obesity crisis extends beyond humans — studies suggest that around 60% of dogs and cats nationwide are overweight.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to "align with federal coverage requirements." ...

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold.

Wegovy is now positioned as the first and only GLP-1 treatment.

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.